Streetbeat News

Earnings

LULU

Lululemon has released its Q2 earnings guidance, projecting EPS between $2.92 and $2.97, which is below the estimated $3.01. Revenue is expected to be between $2.40 billion and $2.42 billion, also below the estimated $2.45 billion.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 8:06 pm

CXM

Sprinklr (NYSE:CXM) reported Q1 2025 adjusted EPS of $0.09, beating the $0.07 estimate, and sales of $195.958M, surpassing the $194.371M estimate. This represents a 50% increase in EPS and a 13.03% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 8:06 pm

LULU

Lululemon Athletica (NASDAQ:LULU) reported Q1 earnings per share (EPS) of $2.54, surpassing the analyst consensus estimate of $2.39. The company also reported quarterly sales of $2.21 billion, exceeding the estimate of $2.20 billion. Both EPS and sales showed significant year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 8:06 pm

FIVE

Five Below has provided its financial outlook for Q2 and FY 2024, with EPS and revenue estimates falling short of analyst expectations. The company expects Q2 EPS to be between $0.57 and $0.69, and FY EPS to be between $4.97 and $5.37. Revenue for Q2 is projected to be between $830 million and $850 million, and for the full year, between $3.79 billion and $3.87 billion.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 8:04 pm

FIVE

Five Below shares are trading lower following worse-than-expected Q1 earnings.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 8:02 pm

FIVE

Five Below (NASDAQ:FIVE) reported Q1 earnings per share (EPS) of $0.57, missing the analyst estimate of $0.64 by 10.94%. Sales were $811.86 million, also below the $836.97 million estimate. EPS decreased by 14.93% year-over-year, while sales increased by 11.79%.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 8:01 pm

BBWI

Bath & Body Works, Inc. (NYSE:BBWI) reported its first-quarter FY24 results with a 5.6% increase in inventories. Analysts from Goldman Sachs, BMO Capital Markets, JP Morgan, and BofA Securities provided their ratings and price forecasts, with a general positive outlook for the second half of the year. BBWI shares are trading higher by 3.74% to $46.86.

Portfolio Pulse from Nabaparna Bhattacharya

June 05, 2024 | 7:27 pm

BULD

PRLB

PRNT

Cantor Fitzgerald analyst Troy Jensen initiated coverage on Proto Labs, Inc. (NYSE:PRLB) with an Overweight rating and a price target of $44.00, citing the company's strong position in the growing digital manufacturing market. The analyst expects Proto Labs to benefit from improving economic conditions and a shift towards digital manufacturing, predicting EPS of $1.50 in FY24 and $1.71 in FY25. Investors can also gain exposure through 3D Printing ETF (BATS:PRNT) and Pacer BlueStar Engineering The Future ETF (NASDAQ:BULD).

Portfolio Pulse from Lekha Gupta

June 05, 2024 | 7:24 pm

AKRO

ETNB

LLY

MDGL

SGMT

VKTX

On Wednesday, Madrigal Pharmaceuticals (MDGL) and Sagimet Biosciences (SGMT) stocks are trading lower following Eli Lilly's (LLY) presentation of positive Phase 2 trial results for tirzepatide in treating MASH at the EASL International Liver Congress 2024. Other companies working on MASH candidates include 89bio (ETNB), Akero Therapeutics (AKRO), and Viking Therapeutics (VKTX).

Portfolio Pulse from Vandana Singh

June 05, 2024 | 7:17 pm

VIR

Vir Biotechnology Inc (NASDAQ:VIR) announced promising preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial, showing high virologic response rates and ALT normalization with tobevibart and elebsiran. The stock rose 18.1% following the news.

Portfolio Pulse from Vandana Singh

June 05, 2024 | 6:51 pm